Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679041 | 1.00 | CA12 (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL9835737 | 0.89 | MAOB (0.54) | CA12CA1CA2CA4CA7 | |
| SCHEMBL10347560 | 0.89 | MAPT (0.56) | CA12CA2CA9DRD2MAPT | |
| SCHEMBL30663731 | 0.89 | MAPT (0.56) | CA12CA2CA9DRD2MAPT | |
| Hydrochloric Acid SCHEMBL21694039 | 0.87 | MAPT (0.55) | CA12CA2CA9DRD2MAPT | |
| SCHEMBL8195926 | 0.83 | MAOB (0.50) | L3MBTL1MAPTMAOBTDP1CYP1A2 | |
| SCHEMBL16378462 | 0.82 | IDO1 (0.43) | CA12CA2CA9L3MBTL1DRD2 | |
| SCHEMBL4090880 | 0.82 | SMN1; SMN2 (0.50) | CA12CA2CA9L3MBTL1DRD2 | |
| SCHEMBL5685999 | 0.82 | SMN1; SMN2 (0.59) | CA12CA1CA2CA4CA7 | |
| SCHEMBL26949012 | 0.81 | MAOB (0.53) | DRD2POLBMAOBMAOAPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761410-B | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022213932-A1 | PYRROLOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药股份有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-114761410-A | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-109096212-B | Method for synthesizing 5-I-1,2, 3-triazole compound by water phase one-pot method | 河南师范大学 | 2021-07-13 | — | — | CN | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| CN-109096212-A | A kind of method of water phase one pot process 5-I-1,2,3- triazole compound | 河南师范大学 | 2018-12-28 | — | — | CN | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3145512-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-103980213-B | Olefin conversion-1,2,3-triazole compound with bacteriostatic activity and preparation method thereof | HENAN NORMAL UNIVERSITY (CN) | 2016-04-27 | — | — | CN | disclosed |
| CN-103058943-B | Diniconazole-1, 2, 3-triazole compound with antibacterial activity and preparation method thereof | UNIV HENAN NORMAL | 2015-05-06 | — | — | CN | disclosed |
| CN-103980213-A | Diniconazole-1,2,3-triazole compounds with antibacterial activity and preparation method thereof | UNIV HENAN NORMAL | 2014-08-13 | — | — | CN | disclosed |
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| CN-103058943-A | Diniconazole-1, 2, 3-triazole compound with antibacterial activity and preparation method thereof | UNIV HENAN NORMAL | 2013-04-24 | — | — | CN | disclosed |
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2004002981-A2 | HERBICIDAL THIENYLALKYNES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-0873993-B1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-02-20 | — | — | EP | disclosed |
| US-5919814-A | Heterocyclic compounds | ADIR ET COMPAGNIE (FR) | 1999-07-06 | — | — | US | disclosed |
| EP-0873993-A1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-10-28 | — | — | EP | disclosed |
| US-4604397-A | Certain benzo-(pyrano and thiopyrano)-pyridines, useful as CNS agents | CIBA-GEIGY CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114063-A1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | BTK, BCL9, LCK | CA12 3785/4885CA1 3296/4885CA2 3325/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | CA12 3785/4885CA1 3296/4885CA2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.